Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06399874 · ClinicalTrials.gov registry record · Phase 2

Nightmare Deconstruction and Reprocessing vs. NightWare Wristband

A Phase 2 study of Nightmare, sponsored by Uniformed Services University of the Health Sciences.

Recruiting
Registry status
Phase 2
Development phase
30
Enrollment target
1
Study location

NCT06399874: Recruiting Phase 2 study of Nightmare, sponsored by Uniformed Services University of the Health Sciences.

NCT06399874 is a Phase 2 study of Nightmare that is actively recruiting participants, run by Uniformed Services University of the Health Sciences. The registered enrollment target is 30 participants, below the 49-participant average among 8 other Nightmare trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06399874, a Phase 2 study of Nightmare, is actively recruiting participants, sponsored by Uniformed Services University of the Health Sciences.

RECRUITING
Registry status
Phase 2
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The overall goal of this Phase IIa randomized controlled pilot trial is to assess the potential efficacy of two emerging treatments for post-trauma nightmares and to test the feasibility of study design and methods. Symptom change will be assessed in two treatment arms: (1) Nightmare Deconstruction and Reprocessing (NDR), an exposure-based psychotherapy; and (2) NightWare (NW), a non-exposure approach using a wristband device. The investigators will also assess the feasibility of circadian-dependent blood sampling and use of another wristband to collect physiologic data. Specific aims are: (1) Compare evidence of how well participants tolerate and comply with the two treatments and test feasibility of methods and procedures; (2) Collect additional evidence of the potential efficacy of two contrasting non-pharmacologic approaches to treating posttraumatic nightmares; (3) Explore the operational stress index (OSI) as a reliable, objective measure of sleep disturbance and nightmare events.

Primary Outcome

The DDNSI is a 5-item self-report instrument used to assess nightmare severity and distress both as an inclusion criterion (score ≥10) and as a primary study variable. Possible score range is 0-37, with a recommended cutoff of 10.

Conditions Studied

Interventions

  • DEVICE NightWare
  • BEHAVIORAL Nightmare Deconstruction and Reprocessing

Study Locations (1)

Maryland

  • Uniformed Services University of the Health Sciences - Bethesda

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-06-11
Est. Completion 2026-03
Phase Phase 2

What NCT06399874 shows while recruiting

NCT06399874 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 49-participant average among 8 other Nightmare trials with a reported enrollment target (39% lower).

The record links to 1 condition, with Nightmare appearing as the primary indexed condition, and to 2 interventions - of which NightWare is the first listed.

NCT06399874 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT06399874 about?

NCT06399874 is a clinical study titled "Nightmare Deconstruction and Reprocessing vs. NightWare Wristband". The overall goal of this Phase IIa randomized controlled pilot trial is to assess the potential efficacy of two emerging treatments for post-trauma nightmares and to test the feasibility of study design and methods. Symptom change will be assessed in two treatment arms: (1) Nightmare Deconstruction ...

What is the current status of trial NCT06399874?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2024-06-11. Estimated completion is 2026-03.

What conditions does trial NCT06399874 study?

This clinical trial studies the following conditions: Nightmare.

What interventions are being tested in trial NCT06399874?

The interventions under investigation include: NightWare (DEVICE), Nightmare Deconstruction and Reprocessing (BEHAVIORAL).

Who is sponsoring clinical trial NCT06399874?

This trial is sponsored by Uniformed Services University of the Health Sciences, which has 27 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06399874 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Nightmare

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06399874's enrollment target sits among peer trials

30 6th of 8 higher than 3 of 8 other Nightmare trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Nightmare trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06399874, the US trial registry maintained by the National Library of Medicine. NCT06399874 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.